OncoTargets and Therapy · 2019 · 32 citations · 24 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyMolecular OncologyBreast Cancer OncologyEpithelial-mesenchymal TransitionEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersFibronectin SignalingFocal Adhesion Kinase SignalingMesenchymal TransitionProtein Kinase B Signaling
Purpose: Oxymatrine, an alkaloid extracted from the Chinese herb Sophora flavescens Aiton, possesses anti-inflammatory, anti-immune, anti-hepatic fibrosis, and anti-cancer properties. However, the effects of oxymatrine on epithelial-mesenchymal transition (EMT) of breast cancer cells are still unclear. Aim: The present study was performed to investigate whether oxymatrine reverses EMT in breast cancer cells and to explore the underlying molecular mechanisms. Materials and methods: MTT assay was performed to evaluate cell viability. Wound-healing assay and transwell chamber assay were used to assess cell migration and invasion, respectively. Immunofluorescence and Western blot were used to study the expression of EMT-related molecules and α Ⅴ β 3 integrin/focal adhesion kinase (FAK)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling transduction. Fibronectin, a physiologic ligand of α Ⅴ β 3 integrin, was used to stimulate α Ⅴ β 3 integrin signaling. Results: Our results demonstrated that oxymatrine effectively suppressed the viability of MDA-MB-231 and 4T1 breast cancer cells, and oxymatrine showed less cytotoxicity on normal breast mammary epithelial MCF-10A cells. In addition, oxymatrine reversed EMT in the MDA-MB-231 and 4T1 cells at nontoxic concentrations. Oxymatrine significantly inhibited cell migration and invasion, downregulated the expression of N-cadherin, vimentin, and Snail in MDA-MB-231 and 4T1 cells, but upregulated the expression of E-cadherin in 4T1 cells. The mechanism revealed that oxymatrine decreased the expression of α Ⅴ and β 3 integrin and their co-localization. It also inhibited α Ⅴ β 3 integrin downstream activation by suppressing the phosphorylation of FAK, PI3K, and Akt. Furthermore, oxymatrine prevented fibronectin-induced EMT and α Ⅴ β 3 integrin/FAK/PI3K/Akt signaling activation. Conclusion: Our results revealed that oxymatrine effectively reversed EMT in breast cancer cells by depressing α Ⅴ β 3 integrin/FAK/PI3K/Akt signaling. Thus, oxymatrine could be a potential therapeutic candidate with anti-metastatic potential for the treatment of breast cancer. Keywords: oxymatrine, breast cancer, α Ⅴ β 3 integrin, epithelial-mesenchymal transition
24
Imagable 4T1 model for the study of late stage breast cancer
Kai Tao, Min Fang, Joseph Alroy et al. · BMC Cancer · 2008 · 522 citations · Full text
Medicine, Immunology, Oncology +14
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto, Lorenzo Gerratana, Elena Poletto et al. · The Oncologist · 2014 · 289 citations · Full text
Medicine, Biostatistics, Oncology +17
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.
Giampietro Gasparini, Peter C. Brooks, Elia Biganzoli et al. · PubMed · 1998 · 280 citations